Cancer Therapeutics Review Branch – CTH
Review Branch Summary
The Cancer Therapeutics Review Branch will consider applications involving translational and clinical investigations that encompass cancer therapeutic development and cancer treatment. Specifically, the Review Branch reviews research grant applications related to drug discovery and mechanism of action of cancer therapeutic agents in both in vitro and in vivo model systems; identification and validation of new druggable targets; development and evaluation of experimental therapies of neoplastic diseases; development or optimization of treatment modalities; and radiation biology and therapy.
Study Sections
- Oncology 2 – Translational Clinical Small Business SBIR/STTR Special Emphasis Panels Cancer Drug Development and Therapeutics (CDDT) SBIR/STTR SEP CTH (10)
- Oncology 2 - Translational Clinical Small Business SBIR/STTR Special Emphasis Panels Radiation Therapy and Biology SBIR RTB SBIR SEPCTH (11)
- Mechanisms of Cancer Therapeutics A MCTA
- Mechanisms of Cancer Therapeutics B MCTB
- Mechanisms of Cancer Therapeutics C MCTC
- Radiation Therapeutics and Biology Study Section RTB
- New! Advancing Therapeutics A*Begins for upcoming October/November 2022 application deadlines, with first review dates in February/March 2023 ATA
- New! Drug Discovery and Molecular Pharmacology C*Begins for upcoming October/November 2022 application deadlines, with first review dates in February/March 2023 DMPC
